Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia
        29 Jan 2022
    byElaine Soliven 
        Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.
Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia
        29 Jan 2022